Which genetic mutations have an adverse effect on the prognosis of acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The presence of an FLT3 mutation is associated with a poorer prognosis. Biallelic mutations in CEBPA are associated with a longer remission duration and longer overall survival. [17] Mutations in NPM are associated with an increased response to chemotherapy. Patients with TP53 mutations have a particularly poor prognosis. [18]

A study by Metzeler et al determined that TET2 mutations had an adverse prognostic impact in an otherwise favorable-risk patient subset, using the European LeukemiaNet (ELN) molecular-risk classification of patients with primary cytogenetically normal AML. [19]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!